| Literature DB >> 35889867 |
Ella Koivuniemi1, Kathryn Hart2, Natalia Mazanowska3, Stefania Ruggeri4, Bernadette Egan5, Laura Censi4, Romana Roccaldo4, Lilja Mattila1, Pasquale Buonocore4, Eliisa Löyttyniemi6, Monique M Raats5, Miroslaw Wielgos3, Kirsi Laitinen1,7,8.
Abstract
The aim was to investigate, among pregnant women, (1) the use of food supplements and (2) the awareness of food supplement recommendations and beliefs about food supplement use in four European countries: Finland, Italy, Poland, and the United Kingdom. The participants (n = 1804) completed an online questionnaire with predefined statements. Daily intakes of vitamins and minerals were calculated using uploaded pictures or weblinks of the supplement packages. Country differences were assessed. Most participants (91%) used at least one food supplement during pregnancy. A prenatal multivitamin was the most commonly used supplement type (84% of the users), and 75% of the participants thought consumption of multivitamin is recommended. Of the participants, 81% knew that folic acid is recommended during pregnancy while 58% knew the recommendation for vitamin D. In 19% of the supplement users, the daily safe upper intake limit of at least one nutrient was exceeded. Nevertheless, most participants agreed that they knew which supplements (91%) and doses of supplements (87%) needed to be used during pregnancy. To conclude, the majority of the participants used food supplements, but lower proportions knew and adhered to the recommended intakes. Between-country differences were observed in the use and knowledge of and beliefs regarding supplements. The results suggest a need for assessment and monitoring of supplement use in antenatal care to ensure appropriate use.Entities:
Keywords: dietary supplement; gestation; mineral; prenatal supplement; vitamin
Mesh:
Substances:
Year: 2022 PMID: 35889867 PMCID: PMC9322729 DOI: 10.3390/nu14142909
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Characteristics of the pregnant women participating in the study (n = 1804).
| All | Finland | Italy | Poland | United Kingdom | |||
|---|---|---|---|---|---|---|---|
| Total | |||||||
|
| 1803/536/555/591/121 | 24.7 (16.7–32.4) | 24.4 (15.2–31.7) | 24.4 (16.7–31.3) | 25.4 (17.1–33.3) | 25.1 (18.0–33.4) | <0.001 a |
|
| 1794/535/551/587/121 | 30.0 (27.0–33.0) | 30.0 (27.0–33.0) | 32.0 (29.0–35.0) | 28.0 (25.0–31.0) | 32.0 (29.0–35.0) | <0.001 a |
| <25 years | 189 (10.5) | 45 (8.4) | 22 (4.0) | 106 (18.1) | 16 (13.2) | <0.001 b | |
| 25–29 years | 662 (36.9) | 217 (40.6) | 142 (25.8) | 283 (48.2) | 20 (16.5) | ||
| 30–34 years | 633 (35.3) | 201 (37.6) | 222 (40.3) | 162 (27.6) | 48 (39.7) | ||
| ≥35 years | 310 (17.3) | 72 (13.5) | 165 (30.0) | 36 (6.1) | 37 (30.6) | ||
|
| 1774/534/547/586/107 | 23.1 (20.7–26.3) | 24.1 (21.5–27.6) | 22.6 (20.4–25.5) | 22.7 (20.5–25.5) | 23.4 (21.5–27.1) | <0.001 a |
| Underweight | 102 (5.7) | 11 (2.1) | 40 (7.3) | 48 (8.2) | 3 (2.8) | <0.001 b | |
| Normal weight | 1111 (62.6) | 313 (58.6) | 365 (66.7) | 369 (63.0) | 64 (59.8) | ||
| Overweight | 362 (20.4) | 112 (21.0) | 93 (17.0) | 133 (22.7) | 24 (22.4) | ||
| Obese | 199 (11.2) | 98 (18.4) | 49 (9.0) | 36 (6.1) | 16 (15.0) | ||
|
| 1788/535/547/587/119 | 1773 (99.2) | 535 (100.0) | 539 (98.5) | 587 (100.0) | 112 (94.1) | <0.001 b |
|
| 1793/534/551/588/120 | <0.001 b | |||||
| Married | 1131 (63.1) | 286 (53.6) | 320 (58.1) | 442 (75.2) | 83 (69.2) | ||
| Living with a partner | 614 (34.2) | 227 (42.5) | 225 (40.8) | 132 (22.4) | 30 (25.0) | ||
| Other | 48 (2.7) | 21 (3.9) | 6 (1.1) | 14 (2.4) | 7 (5.8) | ||
|
| 1795/535/551/588/121 | <0.001 b | |||||
| 1st child | 1205 (67.1) | 336 (62.8) | 359 (65.2) | 430 (73.1) | 80 (66.1) | ||
| 2nd child | 458 (25.5) | 132 (24.7) | 168 (30.5) | 124 (21.1) | 34 (28.1) | ||
| 3rd child or more | 132 (7.4) | 67 (12.5) | 24 (4.4) | 34 (5.8) | 7 (5.8) | ||
|
| 1796/536/551/588/121 | <0.001 b | |||||
| Secondary education or less | 550 (30.6) | 157 (29.3) | 235 (42.7) | 131 (22.3) | 27 (22.3) | ||
| University | 1246 (69.4) | 379 (70.7) | 316 (57.4) | 457 (77.7) | 94 (77.7) | ||
|
| 1712/502/515/576/119 | 476 (27.8) | 229 (45.6) | 119 (23.1) | 88 (15.3) | 40 (33.6) | <0.001 b |
|
| |||||||
| Before pregnancy | 1792/534/551/585/121 | 559 (31.2) | 108 (20.2) | 248 (45.0) | 183 (31.2) | 20 (16.5) | <0.001 b |
| During pregnancy | 1796/534/556/585/121 | 97 (5.4) | 14 (2.6) | 49 (8.9) | 32 (5.5) | 2 (1.7) | <0.001 b |
|
| |||||||
| Before pregnancy | 1792/535/549/587/121 | 1431 (79.9) | 448 (83.7) | 393 (71.6) | 482 (82.1) | 108 (89.3) | <0.001 b |
| During pregnancy | 1791/535/549/587/120 | 99 (5.5) | 8 (1.5) | 71 (13.0) | 5 (0.9) | 15 (12.5) | <0.001 b |
|
| 1774/531/541/581/121 | <0.001 b | |||||
| Low activity | 1259 (71.0) | 268 (50.5) | 448 (82.8) | 480 (82.6) | 63 (52.1) | ||
| Moderate activity | 467 (26.3) | 224 (42.2) | 89 (16.5) | 98 (16.9) | 56 (46.3) | ||
| High activity | 48 (2.7) | 39 (7.3) | 4 (0.7) | 3 (0.5) | 1 (1.7) | ||
|
| |||||||
| Vegetables ≥ 2 times/day | 1795/536/550/588/121 | 777 (43.3) | 315 (58.8) | 113 (20.5) | 281 (47.8) | 68 (56.2) | <0.001 b |
| Fruits and/or berries daily | 1791/534/550/587/120 | 1252 (69.9) | 399 (74.7) | 334 (60.7) | 430 (73.3) | 89 (74.2) | <0.001 b |
| Whole grain products daily | 1793/535/551/587/120 | 979 (54.6) | 420 (78.5) | 183 (33.2) | 299 (50.9) | 77 (64.2) | <0.001 b |
| Fish weekly | 1792/535/550/587/120 | 954 (53.2) | 276 (51.6) | 372 (67.6) | 242 (41.2) | 64 (53.3) | <0.001 b |
| Fast food weekly | 1794/536/551/586/121 | 388 (21.7) | 163 (30.4) | 117 (21.2) | 63 (10.8) | 45 (37.2) | <0.001 b |
|
| 1791/536/549/585/121 | ||||||
| Gestational diabetes | 143 (8.0) | 62 (11.6) | 26 (4.7) | 52 (8.9) | 3 (2.5) | <0.001 b | |
| Pre-eclampsia/high blood pressure | 30 (1.7) | 7 (1.3) | 10 (1.8) | 13 (2.2) | 0 (0.0) | 1.000 b | |
| Pregnancy related nausea | 632 (35.3) | 213 (39.7) | 208 (37.9) | 159 (27.2) | 52 (43.0) | <0.001 b | |
a Comparison between the countries, Kruskal–Wallis test with Bonferroni correction. b Comparison between the countries, Chi-square test with Bonferroni correction.
Reasons for using food supplements during pregnancy reported by pregnant women in four European countries (proportion of women answering ‘yes’ to the statements).
| Finland | Italy | Poland | United Kingdom | ||
|---|---|---|---|---|---|
|
| |||||
| I consume food supplements… | |||||
| as consuming supplements has been recommended for me | 407 (75.9) | 402 (85.9) | 398 (72.0) | 78 (70.3) | <0.001 |
| as I think I don’t get enough nutrients from food | 237 (44.2) | 43 (9.2) | 260 (47.0) | 26 (23.4) | <0.001 |
| as I think consuming supplements is beneficial for me | 376 (70.2) | 91 (19.4) | 257 (46.5) | 42 (37.8) | <0.001 |
| on a regular basis also when not pregnant | 160 (29.9) | 39 (8.3) | 45 (8.1) | 18 (16.2) | <0.001 |
| to be on the safe side | 94 (17.5) | 31 (6.6) | 59 (10.7) | 36 (32.4) | <0.001 |
| to improve my vitality | 95 (17.7) | 38 (8.1) | 47 (8.5) | 9 (8.1) | <0.001 |
| to sleep better | 38 (7.1) | 4 (0.9) | 5 (0.9) | 3 (2.7) | <0.001 |
| to enhance my gut well-being | 94 (17.5) | 25 (5.3) | 20 (3.6) | 9 (8.1) | <0.001 |
| to enhance my immune system | 141 (26.3) | 31 (6.6) | 53 (9.6) | 14 (12.6) | <0.001 |
| to manage my disease | 14 (2.6) | 17 (3.6) | 34 (6.2) | 2 (1.8) | 0.078 |
| to be healthy in general | 148 (27.6) | 76 (16.2) | 117 (21.2) | 14 (12.6) | <0.001 |
| to support exercise | 31 (5.8) | 0 (0.0) | 5 (0.9) | 4 (3.6) | <0.001 |
| as I think consuming food supplements is beneficial for my baby | 422 (78.7) | 199 (42.5) | 369 (66.7) | 76 (68.5) | <0.001 |
| to support the development of my baby | 428 (79.9) | 238 (50.9) | 396 (71.6) | 82 (73.9) | <0.001 |
| to support the growth of my baby | 313 (58.4) | 214 (45.7) | 284 (51.4) | 71 (64.0) | <0.001 |
| Other reason c | 34 (6.3) | 19 (4.1) | 22 (4.0) | 6 (5.4) | 1.000 |
a Proportion of participants answering ‘yes’. b Comparison between the countries, Chi-square test with Bonferroni correction. c Health reasons such as anemia, cramps, restless legs, nausea, vaginal health, and previous gastric bypass; deficiency of some vitamin or mineral; dietary reasons such as following a vegan or vegetarian diet; breastfeeding.
Information sources reported by pregnant women in four European countries that influence their food supplements use.
| Finland | Italy | Poland | United Kingdom | ||
|---|---|---|---|---|---|
|
| |||||
| Partner | 59 (11.0) | 19 (3.5) | 39 (6.7) | 15 (12.4) | <0.001 |
| Parents or other relatives | 46 (8.6) | 14 (2.6) | 34 (5.8) | 13 (10.7) | <0.001 |
| Friends | 87 (16.2) | 5 (0.9) | 30 (5.1) | 13 (10.7) | <0.001 |
| Own initiative | 268 (50.0) | 126 (23.3) | 261 (44.6) | 84 (69.4) | <0.001 |
| Other pregnant women or mothers | 115 (21.5) | 57 (10.6) | 147 (25.1) | 19 (15.7) | <0.001 |
| Midwife/nurse | 431 (80.4) | 168 (31.1) | 75 (12.8) | 90 (74.4) | <0.001 |
| Nutritionist/dietitian | 28 (5.2) | 27 (5.0) | 12 (2.1) | 9 (7.4) | <0.001 |
| Doctor/general physician | 135 (25.2) | 361 (66.9) | 446 (76.2) | 34 (28.1) | <0.001 |
| Pharmacy personnel | 103 (19.2) | 26 (4.8) | 43 (7.4) | 0 (0.0) | <0.001 |
| Herbal shop personnel | 18 (3.4) | 5 (0.9) | 0 (0.0) | 0 (0.0) | <0.001 |
| Adverts | 13 (2.4) | 1 (0.2) | 15 (2.6) | 9 (7.4) | <0.001 |
| Books | 31 (5.8) | 4 (0.7) | 35 (6.0) | 12 (9.9) | <0.001 |
| Magazines or newspapers | 29 (5.4) | 4 (0.7) | 20 (3.4) | 5 (4.1) | <0.001 |
| Social media | 85 (15.9) | 8 (1.5) | 53 (9.1) | 16 (13.2) | <0.001 |
| Mobile applications (apps) | 14 (2.6) | 11 (2.0) | 8 (1.4) | 5 (4.1) | 1.000 |
| Governmental or ministerial websites | 197 (36.8) | 11 (2.0) | 10 (1.7) | 30 (24.8) | <0.001 |
| Commercial websites, blogs | 65 (12.1) | 5 (0.9) | 66 (11.3) | 4 (3.3) | <0.001 |
| Other c | 39 (7.3) | 6 (1.1) | 16 (2.7) | 7 (5.8) | <0.001 |
a Proportion of participants answering ‘yes’. b Comparison between the countries, Chi-square test with Bonferroni correction. c TV or radio, own education or work experience, scientific literature, online pharmacy.
Proportion of women agreeing with the statements regarding beliefs about and intention to use food supplements during pregnancy.
| Total | Finland | Italy | Poland | United Kingdom | ||
|---|---|---|---|---|---|---|
|
|
| |||||
|
| ||||||
| I know which food supplements I need to consume during pregnancy | 523/515/526/112 | 497 (95.0) | 447 (86.8) | 483 (91.8) | 93 (83.0) | <0.001 |
| I know what doses of food supplements I need to consume during pregnancy | 527/502/527/105 | 482 (91.5) | 425 (84.7) | 460 (87.3) | 70 (66.7) | <0.001 |
| I understand how food supplements may impact my health | 517/492/537/106 | 480 (92.8) | 393 (79.9) | 490 (91.2) | 75 (70.8) | <0.001 |
| I believe that consuming food supplements during pregnancy benefit my health, as an expectant mother | 522/513/549/104 | 514 (98.5) | 458 (89.3) | 524 (95.4) | 93 (89.4) | <0.001 |
| I’m unsure of how food supplements benefit the health of my baby | 506/506/545/113 | 88 (17.4) | 170 (33.6) | 115 (21.1) | 38 (33.6) | <0.001 |
| It is easy for me to regularly consume food supplements | 533/518/570/116 | 463 (86.9) | 410 (79.2) | 461 (80.9) | 90 (77.6) | 0.024 |
| More nutrients are needed during pregnancy than before | 509/522/583/107 | 489 (96.1) | 474 (90.8) | 574 (98.5) | 99 (92.5) | <0.001 |
| Absorption of nutrients from the gut is more efficient during | 216/324/181/32 | 156 (72.2) | 112 (34.6) | 53 (29.3) | 15 (46.9) | <0.001 |
| A diverse and healthy diet is the best way to get most nutrients I need | 520/520/550/112 | 481 (92.5) | 478 (91.9) | 529 (96.2) | 108 (96.4) | 0.060 |
| It is necessary to consume particular food supplements in addition to dietary intake during pregnancy | 471/481/527/98 | 248 (52.7) | 389 (80.9) | 464 (88.0) | 84 (85.7) | <0.001 |
| Food supplements used help the baby to grow well | 451/479/520/104 | 366 (81.2) | 420 (87.7) | 478 (91.9) | 89 (85.6) | <0.001 |
| Food supplements used help the baby to develop well | 496/485/536/109 | 479 (96.6) | 449 (92.6) | 508 (94.8) | 103 (94.5) | 0.306 |
| Food supplements used help the baby to be healthy | 393/464/512/105 | 333 (84.7) | 376 (81.0) | 478 (93.4) | 92 (87.6) | <0.001 |
| Food supplements are medicines | 502/481/526/98 | 53 (10.6) | 98 (20.4) | 69 (13.1) | 32 (32.7) | <0.001 |
| Vitamin A is important for the baby’s vision and eye development | 265/260/322/62 | 144 (54.3) | 224 (86.2) | 249 (77.3) | 34 (54.8) | <0.001 |
| A very high intake of vitamin A from supplements during | 444/239/343/93 | 441 (99.3) | 162 (67.8) | 322 (93.9) | 92 (98.9) | <0.001 |
| Vitamin D is needed to ensure the absorption of calcium during pregnancy | 458/337/379/90 | 453 (98.9) | 318 (94.4) | 364 (96.0) | 88 (97.8) | 0.018 |
| Pregnant women generally get enough vitamin D from their food in my country | 481/297/408/104 | 35 (7.3) | 95 (32.0) | 31 (7.6) | 13 (12.5) | <0.001 |
| Pregnant women generally get enough folate from their food in my country | 489/362/466/97 | 25 (5.1) | 61 (16.9) | 64 (13.7) | 10 (10.3) | <0.001 |
| Insufficient intake of folic acid may disturb the development of brain and nervous system of the baby | 498/499/552/112 | 484 (97.2) | 475 (95.2) | 544 (98.6) | 108 (96.4) | 0.096 |
| Sufficient intake of iron during pregnancy prevents tiredness of the mother | 507/472/356/99 | 487 (96.1) | 424 (89.8) | 329 (92.4) | 84 (84.8) | <0.001 |
| Iodine is essential for the baby’s brain and nerve development | 193/221/326/32 | 181 (93.8) | 196 (88.7) | 312 (95.7) | 30 (93.8) | 0.096 |
|
| ||||||
| I’m afraid that consuming food supplements during pregnancy may be harmful for my baby | 501/511/537/114 | 35 (7.0) | 35 (6.8) | 43 (8.0) | 13 (11.4) | 1.000 |
| I’m troubled by the thought that food supplements are highly | 471/481/472/109 | 119 (25.3) | 103 (21.4) | 147 (31.1) | 21 (19.3) | 0.120 |
|
| ||||||
| I’m more willing to consume food supplements when I’m not | 478/490/546/117 | 72 (15.1) | 86 (17.6) | 96 (17.6) | 22 (18.8) | 1.000 |
| I intend to consume food supplements throughout my pregnancy | 520/499/557/114 | 499 (96.0) | 431 (86.4) | 514 (92.3) | 98 (86.0) | <0.001 |
a Comparison of the proportion of women agreeing and disagreeing with the statements between the countries. ‘Not sure’ answers were removed from the analyses. b Comparison between the countries, Chi-square test with Bonferroni correction.
Likelihood of any food supplement use according to selected sociodemographic and behavioral factors characterizing pregnant women in four European countries.
| Total | Adjusted OR a | 95 % Confidence Interval | ||
|---|---|---|---|---|
|
| ||||
|
| 1794 | 0.48 | ||
| <25 years | 1 | |||
| 25–29 years | 1.513 | 0.828–2.766 | ||
| 30–34 years | 1.255 | 0.690–2.281 | ||
| ≥35 years | 1.128 | 0.590–2.157 | ||
|
| 1774 | 0.50 | ||
| Underweight | 1 | |||
| Normal weight | 1.476 | 0.796–2.736 | ||
| Overweight | 1.225 | 0.617–2.434 | ||
| Obese | 1.689 | 0.730–3.905 | ||
|
| 1793 | 0.063 | ||
| Living with a partner | 1 | |||
| Married | 1.343 | 0.943–1.911 | ||
| Other | 0.546 | 0.213–1.399 | ||
|
| 1795 | 0.0004 | ||
| 1st child | 1 | |||
| 2nd or more | 1.852 | 1.317–2.606 | ||
|
| 1796 | 0.47 | ||
| Secondary education or less | 1 | |||
| University | 1.140 | 0.800–1.625 | ||
|
| 1712 | 0.52 | ||
| No | 1 | |||
| Yes | 1.153 | 0.751–1.770 | ||
|
| ||||
|
| 1794 | 0.047 | ||
| No | 1 | |||
| Yes | 0.676 | 0.460–0.994 | ||
|
| 1792 | 0.45 | ||
| Not at all | 1 | |||
| <1 drink per week | 1.396 | 0.909–2.141 | ||
| 1–2 drinks per week | 1.159 | 0.731–1.837 | ||
| 3–7 drinks per week | 1.740 | 0.837–3.615 | ||
| >7 drinks per week | 0.940 | 0.259–3.409 | ||
|
| 1774 | 0.73 | ||
| Low activity | 1 | |||
| Moderate activity | 0.894 | 0.586–1.364 | ||
| High activity | 1.796 | 0.233–13.811 | ||
|
| 1795 | 0.47 | ||
| No | 1 | |||
| Yes | 1.151 | 0.787–1.682 | ||
|
| 1791 | 0.75 | ||
| No | 1 | |||
| Yes | 0.942 | 0.658–1.350 | ||
|
| 1635 | 0.83 | ||
| No | 1 | |||
| Yes | 1.038 | 0.730–1.475 | ||
|
| 1792 | 0.91 | ||
| No | 1 | |||
| Yes | 0.980 | 0.690–1.391 |
a Adjusted by country. b Logistic regression analysis with a univariate approach.
Figure 1Proportion of supplement users using one or more food supplement products.
Daily intakes of nutrients from food supplements and adherence to food supplement recommendations in pregnant women who reported their supplement use with pictures and/or detailed written information.
| Finland | Italy | Poland | United Kingdom | ||
|---|---|---|---|---|---|
|
| |||||
|
| |||||
| User, | 4 (0.9) | 31 (8.6) | 7 (1.6) | 1 (1.0) | <0.001 a |
| Dose, median (IQR) | 400.0 (325.0–700.0) | 300.0 (300.0–300.0) | 800.0 (640.0–800.0) | 800.0 | 0.036 b |
| Dose, range | 300.0–800.0 | 300.0–1080.0 | 400,0–1080.0 | - | |
| Women exceeding the daily safe upper intake limit of 3000 µg/d c, | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||
| User, | 404 (86.0) | 284 (78.9) | 310 (70.6) | 79 (81.4) | <0.001 a |
| Dose, median (IQR) | 5.0 (2.8–5.0) | 1.9 (1.4–1.9) | 2.6 (2.2–5.0) | 10.0 (1.9–10.0) | <0.001 b |
| Dose, range | 0.5–51.2 | 0.6–20.9 | 0.6–100.0 | 1.4–30.0 | |
| Women exceeding the daily safe upper intake limit of 25 mg/d c, | 6 (1.5) | 0 (0.0) | 16 (5.2) | 1 (1.3) | |
|
| |||||
| User, | 437 (93.0) | 342 (95.0) | 432 (98.4) | 92 (94.8) | 0.006 a |
| Dose, median (IQR) | 400.0 (400.0–500.0) | 400.0 (400.0–400.0) | 800.0 (400.0–800.0) | 400.0 (400.0–400.0) | <0.001 b |
| Dose, range | 100.0–1500.0 | 142.9–16200.0 | 114.3–6600.0 | 171.4–5400.0 | |
| Women meeting the recommended dose, | 240 (54.9) | 258 (75.4) | 112 (26.0) | 83 (90.2) | |
| Women exceeding the recommended dose, | 151 (34.6) | 74 (21.6) | 303 (70.1) | 7 (7.6) | |
| Women exceeding the daily safe upper intake limit of 1000 µg/d c, | 7 (1.6) | 43 (12.6) | 43 (10.0) | 2 (2.2) | |
|
| |||||
| User, | 456 (97.0) | 277 (76.9) | 399 (90.9) | 92 (94.8) | <0.001 a |
| Dose, median (IQR) | 10.0 (10.0–20.0) | 12.5 (10.0–15.0) | 50.0 (20.0–50.0) | 10.0 (10.0–10.0) | <0.001 b |
| Dose, range | 0.9–253.3 | 3.6–250.0 | 2.5–332.5 | 4.3–85.0 | |
| Women meeting the recommended dose, | 266 (58.3) | - | 224 (56.1) | 77 (83.7) | |
| Women exceeding the recommended dose, | 151 (33.1) | - | 31 (7.8) | 13 (14.1) | |
| Women exceeding the daily safe upper intake limit of 100 µg/d c, | 9 (2.0) | 5 (1.8) | 7 (1.8) | 0 (0.0) | |
|
| |||||
| User, | 385 (81.9) | 166 (46.1) | 215 (49.0) | 71 (73.2) | <0.001 a |
| Dose, median (IQR) | 15.0 (12.0–15.0) | 12.0 (8.0–12.0) | 11.7 (11.7–23.4) | 4.0 (4.0–12.0) | <0.001 b |
| Dose, range | 2.3–30.0 | 3.0–280.0 | 1.0–130.0 | 1.7–200.0 | |
| Women exceeding the daily safe upper intake limit of 300 mg/d c, | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||
| User, | 113 (24.0) | 114 (31.7) | 40 (9.1) | 36 (37.1) | <0.001 a |
| Dose, median (IQR) | 500.0 (400.0–750.0) | 140.0 (140.0–242.5) | 200.0 (200.0–240.0) | 200.0 (120.0–500.0) | <0.001 b |
| Dose, range | 42.9–1100.0 | 36.9–731.0 | 70.0–1000.0 | 120.0–1120.0 | |
| Women exceeding the daily safe upper intake limit of 2500 mg/d c, | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||
| User, | 390 (83.0) | 181 (50.3) | 241 (54.9) | 77 (79.4) | <0.001 a |
| Dose, median (IQR) | 180.0 (180.0–180.0) | 110.0 (60.0–110.0) | 90.0 (50.0–193.0) | 150.0 (150.0–150.0) | <0.001 b |
| Dose, range | 37.5–930.0 | 9.0–1140.0 | 2.4–600.0 | 60.0–410.0 | |
| Women exceeding the daily safe upper intake limit of 250 mg/d c, | 76 (19.5) | 52 (28.7) | 28 (11.6) | 3 (3.9) | |
|
| |||||
| User, | 382 (81.3) | 266 (73.9) | 99 (22.6) | 77 (79.4) | <0.001 a |
| Dose, median (IQR) | 15.0 (10.7–15.0) | 10.0 (10.0–11.0) | 15.0 (11.0–15.0) | 15.0 (15.0–15.0) | <0.001 b |
| Dose, range | 2.0–40.0 | 0.9–22.5 | 3.8–101.0 | 6.4–25.0 | |
| Women exceeding the daily safe upper intake limit of 25 mg/d c, | 4 (1.0) | 0 (0.0) | 2 (2.0) | 0 (0.0) | |
|
| |||||
| User, | 369 (78.5) | 210 (58.3) | 138 (31.4) | 77 (79.4) | <0.001 a |
| Dose, median (IQR) | 60.0 (55.0–60.0) | 55.0 (30.0–55.0) | 55.0 (55.0–55.0) | 30.0 (30.0–55.0) | <0.001 b |
| Dose, range | 12.5–88.0 | 12.5–112.5 | 16.0–200.0 | 12.9–150.0 | |
| Women exceeding the daily safe upper intake limit of 300 µg/d c, | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
|
| |||||
| User, | 379 (80.6) | 266 (3.9) | 378 (86.1) | 76 (78.4) | <0.001 a |
| Dose, median (IQR) | 175.0 (175.0–200.0) | 200.0 (175.0–220.0) | 200.0 (150.0–200.0) | 150.0 (150.0–150.0) | <0.001 b |
| Dose, range | 37.5–220.0 | 64.3–440.0 | 50.0–400.0 | 50.0–290.0 | |
| Women meeting the recommended dose, | - | - | 241 (63.8) | - | |
| Women exceeding the recommended dose, | - | - | 14 (3.7) | - | |
| Women exceeding the daily safe upper intake limit of 600 µg/d c, | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
a Comparison between the countries, Chi-square test with Bonferroni correction. b Comparison between the countries, Kruskal–Wallis test with Bonferroni correction. c Safe upper intake limit reported as set by the European Food Safety Authority [22]. d Recommended intake of folic acid from supplements during pregnancy: 400 µg/d in each country in the low-risk group. e Recommended intake of vitamin D from supplements during pregnancy: 10 µg/d in Finland and the UK, 50 µg/d in Poland, no recommendation in Italy. f Recommended intake of iodine from supplements during pregnancy: 200 µg/d in Poland, no recommendation in other countries.
Figure 2Proportion of participants reporting in an online survey that specific supplements are recommended for use before and during pregnancy and during breastfeeding by country of residence: (A) folic acid; (B) vitamin D; (C) multivitamin supplement. Finland, n = 536; Italy, n = 540; Poland, n = 585; the United Kingdom, n = 121.